Titanovo Logo
Back to Cell Types

ZR-75-30Homo sapiens (Human)Cancer cell line

Also known as: ZR75-30, ZR7530

🤖 AI SummaryBased on 16 publications

Quick Overview

Human breast cancer cell line with genomic instability and therapeutic resistance.

Detailed Summary

ZR-75-30 is a human breast cancer cell line derived from a metastatic lesion, characterized by complex genomic alterations and high levels of chromosomal instability. It exhibits a highly aneuploid karyotype with multiple chromosomal rearrangements, including amplifications and deletions. This cell line has been extensively studied for its role in understanding breast cancer biology, particularly in the context of therapeutic resistance and gene fusion events. ZR-75-30 is commonly used in research to investigate the molecular mechanisms underlying breast cancer progression and response to targeted therapies.

Research Applications

Genomic instability studiesTherapeutic resistance mechanismsGene fusion analysisChromosomal rearrangement characterization

Key Characteristics

Highly aneuploid karyotypeComplex chromosomal rearrangementsAmplifications and deletionsExpression of fusion genes
Generated on 6/17/2025

Basic Information

Database IDCVCL_1661
SpeciesHomo sapiens (Human)
Tissue SourceAscites[UBERON:UBERON_0007795]

Donor Information

Age47
Age CategoryAdult
SexFemale
Raceblack_or_african_american
Subtype FeaturesER+, PR+, HER2+

Disease Information

DiseaseInvasive breast carcinoma of no special type
LineageBreast
SubtypeBreast Invasive Lobular Carcinoma
OncoTree CodeILC

DepMap Information

Source TypeATCC
Source IDACH-000828_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
Gene fusionAPPBP2APPBP2-PHF20L1-In framePubMed=23260012
Gene fusionBCAS3BCAS3-HOXB9--PubMed=23260012
Gene fusionCOL14A1COL14A1-SKAP1-In framePubMed=23260012
Gene fusionDDX5DDX5-DEPTOR-In framePubMed=23260012
Gene fusionBCAS3ERBB2-BCAS3-Out of framePubMed=23260012
Gene fusionENPP2PLEC-ENPP2, PLEC1-ENPP2-In framePubMed=23260012
Gene fusionPCGF2TAOK1-PCGF2-In framePubMed=23260012
Gene fusionNRIP1TIAM1-NRIP1-In framePubMed=23260012
Gene fusionARHGAP32TIMM23-ARHGAP32-Out of framePubMed=23260012
Gene fusionLASP1TRPS1-LASP1-In framePubMed=23260012
Gene fusionCWC25USP32-CWC25, USP32-CCDC49-Out of framePubMed=23260012
Gene fusionOPRD1ZMYM4-OPRD1-Out of framePubMed=23260012
MutationSimpleBRAFp.Ile326Thr (c.977T>C)Heterozygous-PubMed=19593635
MutationSimpleCDH1p.Glu243Ter (c.727G>T)Homozygous-PubMed=19593635

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10,11
D13S317
10,11
D16S539
9
D18S51
17
D19S433
13.2,14.2
D21S11
31
D2S1338
17,22
D3S1358
15,18
D5S818
12,13
D7S820
11,12
D8S1179
13,14
FGA
22
Penta D
2.2,10
Penta E
5,7
TH01
8,9
TPOX
10,11
vWA
18,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Cell lines from human breast.";

Leibovitz A.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).

DOI

Establishment and characterization of three new continuous cell lines derived from human breast carcinomas.

Joyce M.J.

Cancer Res. 38:3352-3364(1978).

PubMed

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

PubMed

Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.

Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.

Cancer Res. 60:4519-4525(2000).

PubMed

Molecular cytogenetic analysis of breast cancer cell lines.";

Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.

Br. J. Cancer 83:1309-1317(2000).

DOIPubMedPMC

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

Wolf E., Gabius H.-J.

J. Cancer Res. Clin. Oncol. 127:375-386(2001).

DOIPubMed

BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.

van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.

Cancer Res. 66:41-45(2006).

DOIPubMed

Comprehensive copy number profiles of breast cancer cell model genomes.

Shadeo A., Lam W.L.

Breast Cancer Res. 8:R9.1-R9.14(2006).

DOIPubMedPMC

Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.

Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.

Breast Cancer Res. Treat. 99:97-101(2006).

DOIPubMed

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.

Cancer Cell 10:515-527(2006).

DOIPubMedPMC

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

Pollack J.R.

PLoS ONE 4:E6146-E6146(2009).

DOIPubMedPMC

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.

den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.

Breast Cancer Res. Treat. 121:53-64(2010).

DOIPubMed

Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

Yamamoto S., Oka M., Hirano T., Sasaki K.

BMC Cancer 10:15.1-15.10(2010).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Molecular characterisation of cell line models for triple-negative breast cancers.

Reis-Filho J.S., Tutt A.

BMC Genomics 13:619.1-619.14(2012).

DOIPubMedPMC

Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes.

Edwards P.A.W.

BMC Genomics 13:719.1-719.11(2012).

DOIPubMedPMC

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.

Martens J.W.M.

Breast Cancer Res. 15:R33.1-R33.17(2013).

DOIPubMedPMC

Cell surface-specific N-glycan profiling in breast cancer.";

Shi S.-L., Chen C.-Y., Li Y.

PLoS ONE 8:E72704-E72704(2013).

DOIPubMedPMC

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

McCormick F., Gray J.W.

Cancer Cell 24:450-465(2013).

DOIPubMedPMC

Modeling precision treatment of breast cancer.";

Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Genome Biol. 14:R110.1-R110.14(2013).

DOIPubMedPMC

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

DOIPubMedPMC

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

DOIPubMedPMC

Web Resources

cellosaurus.orglincs.hms.harvard.edusynapse.orgtcpaportal.org